Instrument Inactif

Communiqués Chromadex Corp OTC Bulletin Board

Actions

CDXC

US1710771007

Recherche biotechnologique et médicale

Cours en clôture OTC Bulletin Board Autres places de cotation
- ^USD	-

18:36	Niagen Bioscience lance son programme pharmaceutique et positionne le NB4168 comme premier candidat-médicament contre le vieillissement accéléré et les maladies génétiques rares	CI
15:33	Niagen Bioscience lance un programme de développement de thérapies contre le vieillissement accéléré et les maladies génétiques rares	MT

Communiqués

14:32	Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases	BU
03/06	Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference	BU
02/06	Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science	BU
08/05	Niagen Bioscience Announces Participation in Upcoming Investor Conferences	BU
07/05	Niagen Bioscience : May 2026 Investor Presentation	PU
06/05	Niagen Bioscience: Q1 Earnings Snapshot	AQ
06/05	Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results	BU
04/05	Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering	BU
28/04	Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™	BU
22/04	Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026	BU
09/04	Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®	BU
01/04	Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpa World, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas	AQ
31/03	Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas	BU
24/03	Four Stocks at the Intersection of Enzymes, Longevity, and the $400 Billion Wellness Boom (CELV, NAGE, MTEX, CDXS)	AQ
19/03	Niagen Bioscience Increases Share Repurchase Program to $20 Million	BU
18/03	Niagen Bioscience to Present at the 38th Annual ROTH Conference	BU
17/03	Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies	BU
11/03	Niagen Bioscience Launches Niagen(R) Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud, From Tru Niagen Powered by Patented Niagen(R)	AQ
10/03	Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®	BU
04/03	Niagen Bioscience : March 2026 Investor Presentation	PU
04/03	Niagen Bioscience: Q4 Earnings Snapshot	AQ
04/03	Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025	BU
03/03	Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone	AQ
26/02	Niagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotinamide Riboside, Niagen	AQ
26/02	Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction	BU